INNOVIVA INC

INVANASDAQ

🏆 #2169 by market capEarnings Nov 3US Equity

$385.43▼ $25.79 (−6.69%)

Simulated price

🔔

Track INVA

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 6.7%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1.57B

Small Cap

📈Revenue Growth (YoY)

+18.5%

Healthy

📊Gross Margin

73.1%

High

💵FCF Margin

42.5%

Strong

⚖️P/S Ratio

3.5x

Fair

Otter Score

Fair

No chart data available for INVA.

Trading Snapshot

Day Range: $380.58 – $389.31
52-Week Range: $16.52 – $25.15
Volume: $2.01B
Avg Volume: $1.80B
Shares Outstanding: 73.8M
Next Earnings: Nov 28, 2026

Fundamentals Snapshot

Annual Revenue: $425M
Last Q Revenue: $120M
P/E Ratio: 4.4
P/S Ratio: 3.5x
EPS (TTM): $4.87
Dividend Yield: 0.00%
Dilution (1yr): +1.3%

Why Investors Own INVA

✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
✓Healthy economics — 79% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INNOVIVA INC

INVA

Financial Trends

Revenue

$425M▲ +18.5% YoY

Gross Margin

72.3%▼ −19.4% YoY

Operating Income

$164M▼ −1.9% YoY

Free Cash Flow

$186M▼ −1.1% YoY

Shares Outstanding

85.3M▲ +1.3% YoY

Net Cash

$282M▲ +$428M YoY

StockOtter · stockotter.space

About INNOVIVA INC

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

🦦